scholarly journals TET2 Driven Clonal Hematopoiesis Promotes Allograft Tolerance in a Mouse Heart Transplant Model

2021 ◽  
Vol 40 (4) ◽  
pp. S228
Author(s):  
L.R. Gokanapudy Hahn ◽  
S. Yang ◽  
A. Bredemeyer ◽  
H. Dun ◽  
I. Lokshina ◽  
...  
2011 ◽  
Vol 34 (2) ◽  
pp. 86-91 ◽  
Author(s):  
Song Su ◽  
Tobias R. Türk ◽  
Shengli Wu ◽  
Hua Fan ◽  
Jian Fu ◽  
...  

1999 ◽  
Vol 67 (7) ◽  
pp. S119
Author(s):  
H. Wang ◽  
M. E. DeVries ◽  
B. Garcia ◽  
D. Kelvin ◽  
R. Zhong

2000 ◽  
Vol 69 (Supplement) ◽  
pp. S382
Author(s):  
Hao Wang ◽  
Mark E. DeVries ◽  
Masud H. Khandaker ◽  
Shaoping Deng ◽  
Bertha Garcia ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jian Lu ◽  
Weiwei Wang ◽  
Peiyuan Li ◽  
Xiaodong Wang ◽  
Chao Gao ◽  
...  

AbstractRegulatory T cells (Tregs), which characteristically express forkhead box protein 3 (Foxp3), are essential for the induction of immune tolerance. Here, we investigated microRNA-146a (miR-146a), a miRNA that is widely expressed in Tregs and closely related to their homeostasis and function, with the aim of enhancing the function of Tregs by regulating miR-146a and then suppressing transplant rejection. The effect of the absence of miR-146a on Treg function in the presence or absence of rapamycin was detected in both a mouse heart transplantation model and cell co-cultures in vitro. The absence of miR-146a exerted a mild tissue-protective effect by transiently prolonging allograft survival and reducing the infiltration of CD4+ and CD8+ T cells into the allografts. Meanwhile, the absence of miR-146a increased Treg expansion but impaired the ability of Tregs to restrict T helper cell type 1 (Th1) responses. A miR-146a deficiency combined with interferon (IFN)-γ blockade repaired the impaired Treg function, further prolonged allograft survival, and alleviated rejection. Importantly, miR-146a regulated Tregs mainly through the IFN-γ/signal transducer and activator of transcription (STAT) 1 pathway, which is implicated in Treg function to inhibit Th1 responses. Our data suggest miR-146a controls a specific aspect of Treg function, and modulation of miR-146a may enhance Treg efficacy in alleviating heart transplant rejection in mice.


2001 ◽  
Vol 33 (3) ◽  
pp. 2170-2171 ◽  
Author(s):  
J Klupp ◽  
T van Gelder ◽  
C Dambrin ◽  
J Regieli ◽  
K Boeke ◽  
...  

Author(s):  
Jerome H. Klotz ◽  
Linda D. Sharpless

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4960-4960
Author(s):  
Wenda Gao ◽  
Kenichiro Yamashita ◽  
Jennifer Sullivan ◽  
Abraham Scaria ◽  
Terry B. Strom ◽  
...  

Abstract Program death-1 (PD-1) is a negative regulator of the immune system. Blocking PD-1-mediated negative signaling accelerates autoimmune diseases, while engaging PD-1 with recombinant PD-L1Ig fusion protein potentiates the efficacy of co-stimulation blockade in prolonging allograft survival. However, soluble PD-L1Ig itself showed no graft-protecting effect, in contrast to its strong inhibition of T and B cell activation in vitro when applied in a plate-bound form. In this study, we tested the hypothesis that membrane-bound PD-L1 should prolong allograft survival due to its increased ability to crosslink PD-1 receptor. An adenovirus (Ad.PD-L1) was constructed to encode the full-length mPD-L1, followed by green fluorescent protein (GFP) gene linked by an IRES sequence. A control adenovirus (Ad.Ctrl) was similarly constructed that carries only the GFP gene. In islet transplant model, B6AF1 (H-2b/a) islets were infected with the adenoviruses, and then transplanted into C57BL/6 (H-2b) mice induced diabetic by streptozotocin. In heart transplant model, DBA/2 (H-2d) hearts were perfused with adenoviruses, and then transplanted into C57BL/6 mice. PD-L1 over-expression in islet did not prolong graft survival, but accelerated islet rejection (Ad.PD-L1: 9.0+/−3.5 days; Ad.Ctrl: 13.3+/−2.2 days). In contrast, infection with Ad.PD-L1 prolonged heart allograft survival (15.4+/−5.7 days) in C57BL/6 mice, which promptly rejected DBA/2 hearts (7.0+/−2.3 days, p<0.02). Thus, over-expression of membrane-bound PD-L1 has beneficial effect in an organ/tissue specific manner. Strategies other than direct expression of PD-L1 in the islet b cells need to be devised in order to utilize this negative pathway to prevent rejection.


Sign in / Sign up

Export Citation Format

Share Document